Kardiorespirator tadqiqotlar jurnali 2022-№2.1.pdf
Subject of the article
YURAK ISHEMIK KASALLIGI MAVJUD BEMORLARDA TROMBOSITLAR AGREGASIYASI TEKSHIRUVIDA ANTIAGREGANT DAVOGA NISBATAN REZISTENTLIK HOLATI (61-65)
Authors
Хodjanova Sh.I., Alyavi A.L.
Institution
Respublika ixtisoslashtirilgan terapiya va tibbiy reabilitasiya ilmiy-amaliy tibbiyot markazi
Abstract
So‘nggi yillarda olib borilgan tadqiqotlarda yurak ishemik kasalligi patogenezida trombositar gemostaz tizimidagi buzilishlar va aspiringa rezistentlikning yuzaga kelishi ishemik hodisalar xavfini deyarli ikki barobar oshirishi tasdiqlangan. Bu yurak ishemik kasalligi davosini nazorat qilish, o‘z vaqtida monand antiagregant davo rejasini tayinlashga qaratilgan zamonaviy yondashuvlar ishlab chiqilishini taqozo qiladi. Tadqiqotning maqsadi asetilsalisil kislotani qisqa va uzoq muddat qabul qiladigan yurak ishemik kasalligi turg‘un zo‘riqish stenokardiyasi (TZS) II-III funksional sinfi bilan og‘rigan bemorlarda trombositlar funksional holatini baholashdan iborat. Material va uslublar.Tadqiqot manbasi sifatida turg‘un zo‘riqish stenokardiyasi II–III funksional sinfi tashxisi bilan davolangan 116 nafar bemorlar tanlandi. TZSli bemorlar asetilsalisil kislotasi qabul qilish davomiyligiga ko‘ra to‘rt guruhga ajratildi. 1-guruhni bir yilgacha ASK qabul qilgan, 2-guruhni ASKni 1 yildan 5 yilgacha bo‘lgan muddatda qabul qilgan, 3-guruhniASKni 5 yildan ko‘p muddat davomida qabul qilayotgan bemorlar hamda nazorat guruhini ASK qabul qilmagan bemorlar tashkil etdi. Trombositlar agregasiyasi tekshiruvi Born va O’Brayen bo‘yicha an'anaviy turbidometrik usulda AGGR dasturi bo‘yicha komp'yuterli qayta ishlash orqali ikki kanalli lazerli Alat – 2 Biola analizatorida bajarildi. Natijalar. 5 yildan ko‘p muddat aspirin qabul qilgan bemorlar guruhida trombositlar spontan agregasiyasi va ADF-indusirlangan agregasiyasi ko‘rsatkichlari 1 yilgacha ASK qabul qilgan va 1 yildan 5 yilgacha ASK qabul qilgan bemorlar guruhi ko‘rsatkichlariga nisbatan yuqori bo‘lib, statistik ishonarli farqlar 1 yilgacha ASK qabul qilgan bemorlar guruhi ko‘rsatkichlariga nisbatan kuzatildi (spontan agregasiya 1,7±0,09 r<0,05, 0,1 mkm ADF-indusirlangan agregasiya 6,58±0,86 r<0,05, 1,0 ADFindusirlangan agregasiya 16,51±1,63 r<0,01, 5,0 ADF-indusirlangan agregasiya 58,44±3,72 r<0,01). 5 yildan ortiq ASK qabul qilgan bemorlardan iborat uchinchi guruhda 5 yilgacha ASK qabul qilgan bemorlardan iborat ikkinchi guruhga nisbatan aspiringa rezistentlik sezilarli darajada ko‘proq qayd etildi (mos ravishda 54,8% va 29% Xi2=4,24 r<0,05). Shu bilan birga, 1 yilgacha ASK qabul qilgan 1-guruh bemorlarda rezistentlik uchrashi 5 yildan ortiq ASK qabul qilgan bemorlarga nisbatan kamroq kuzatildi (mos ravishda 13,3% va 54,8% Xi2=11,63 r<0,05). Xulosa. Yurak ishemik kasalligida aspirin bilan davolashning 5 yildan ortiq davom etishida trombositlar agregasiya ko‘rsatkichlarining oshishi aspiringa rezistentlik xavfi bilan o‘zaro bog‘liqdir.
Key words
yurak ishemik kasalligi, aspiringa rezistentlik, trombositlar agregasiyasi
Literature
Бокарев И.Н. Резистентность к антитромбоцитарным препаратам // Сердце: журнал для практикующих врачей. - 2012.- Т. 11. № 2. -С. 103-107. 2. Боровков Н.Н. Ацетилсалициловая кислота остается «золотым стандартом» антиагрегантной терапии стабильной стенокардии // Справочник поликлинического врача. -2014. -№ 2. -С. 26-28. 3. Воробьева, Н.М. Первичная профилактика сердечно-сосудистых заболеваний: эффективность и безопасность ацетилсалициловой кислоты // Русский медицинский журнал. - 2014. - № 12. - С. 916-921. 4. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. ESC Thrombosis Working Group. // Eur Heart J. – 2015. – 7;36 (46). – Р. 3238-49. 5. Chadha D.S., Budha Sumana, Ganesan Karthikeyan et.al. Prevalence of aspirin resistance in Asian-Indian patients with stable coronary artery disease. Catheterization and Cardiovascular Interventions. 2014. Vol 88, Issue 4 p.126-131. https://doi.org/10.1002/ccd.25420. 6. Frank L J Visseren, François Mach, Yvo M Smulders, David Carballo et. al. ESC Scientific Document Group, 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC), European Heart Journal, Volume 42, Issue 34, 7 September 2021, Pages 3227– 3337, https://doi.org/10.1093/eurheartj/ehab484. 7. Juhani Knuuti, William Wijns, Antti Saraste, Davide Capodanno et.al. ESC Scientific Document Group, 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC), European Heart Journal, Volume 41, Issue 3, 14 January 2020, Pages 407– 477, https://doi.org/10.1093/eurheartj/ehz425. 8. Parvin Ebrahimi, MSc, Zeynab Farhadi et al. Prevalence rate of laboratory defined aspirin resistance in cardiovascular disease patients: A systematic review and meta-analysis// Caspian J Intern Med.-2020-Vol.11(2).-P. 124-134. 9. Philipp N., Walter et al. Antiplatelet resistance in outpatients with monitored adherence //Platelets.-2017-Vol. 25(7).-P. 1-5. 10. Raichand, S., Moore D., Riley R.D. et. al. Protocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease // Syst Rev. – 2013. – Vol.2. – Р. 16. 11. Salman H., Maraan A., et.al. Chronic Coronary Syndrome: A Review of the Literature. Annals of Clinical Cardiology 2020, 3(1). doi: 10.4103/ACCJ.ACCJ_21_20. 12. Serkan Kahraman, Ali Dogan, Murat Ziyrek, et al. The association between aspirin resistance and extent and severity of coronary atherosclerosis. // North Clin Istanb.- 2018-Vol. 5(4).-P. 323–328.